NASDAQ:DRRXDURECT Stock Price, Forecast & News

$2.34

-0.04 (-1.68 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$2.17

Now: $2.34▼

$2.47

50-Day Range

$1.57

MA: $2.16▼

$2.73

52-Week Range

$0.50

Now: $2.34▼

$3.95

Volume3.29 million shs

Average Volume1.08 million shs

Market Capitalization$458.69 million

P/E RatioN/A

Dividend YieldN/A

Beta2.22

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
DURECT has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.53, DURECT has a potential upside of 93.4% from its current price of $2.34.
Amount of Analyst Coverage
DURECT has only been the subject of 2 research reports in the past 90 days.

3.0 Community Rank

Outperform Votes
DURECT has received 294 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
DURECT has received 199 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
DURECT has received 59.63% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote “Outperform” if you believe DRRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
DURECT does not currently pay a dividend.
Dividend Growth
DURECT does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DURECT insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $98,470.00 in company stock.
Percentage Held by Insiders
Only 10.20% of the stock of DURECT is held by insiders.
Percentage Held by Institutions
49.95% of the stock of DURECT is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for DURECT are expected to grow in the coming year, from ($0.18) to ($0.13) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of DURECT is -19.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of DURECT is -19.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
DURECT has a P/B Ratio of 33.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.61 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:DRRX

Previous Symbol

CUSIPN/A

CIK1082038

Webwww.durect.com

Phone408-777-1417

Debt

Debt-to-Equity Ratio1.75

Current Ratio2.57

Quick Ratio2.43

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$29.56 million

Price / Sales15.52

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.07 per share

Price / Book33.43

Profitability

EPS (Most Recent Fiscal Year)($0.12)

Net Income$-20,580,000.00

Net Margins-82.94%

Return on Equity-114.36%

Return on Assets-30.35%

Miscellaneous

Employees88

Outstanding Shares196,020,000

Market Cap$458.69 million

Next Earnings Date8/6/2020 (Estimated)

OptionableOptionable

Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.

DURECT (NASDAQ:DRRX) Frequently Asked Questions

How has DURECT's stock been impacted by COVID-19 (Coronavirus)?

DURECT's stock was trading at $1.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DRRX shares have increased by 41.8% and is now trading at $2.34. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of DURECT?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DURECT.

When is DURECT's next earnings date?

DURECT is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for DURECT.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) issued its quarterly earnings data on Monday, May, 11th. The specialty pharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. The specialty pharmaceutical company had revenue of $2.78 million for the quarter, compared to analyst estimates of $4.74 million. DURECT had a negative return on equity of 114.36% and a negative net margin of 82.94%. View DURECT's earnings history.

What price target have analysts set for DRRX?

5 brokers have issued 1 year price targets for DURECT's shares. Their forecasts range from $2.10 to $6.00. On average, they expect DURECT's stock price to reach $4.53 in the next year. This suggests a possible upside of 93.4% from the stock's current price. View analysts' price targets for DURECT.

What are Wall Street analysts saying about DURECT stock?

Here are some recent quotes from research analysts about DURECT stock:

1. According to Zacks Investment Research, "Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from the medical device and drug delivery industries with its proprietary pharmaceutical and biotechnology drug formulations. " (5/8/2020)
2. HC Wainwright analysts commented, "Recently Signed Gilead Partnership Yields First $10M Milestone; Affirm Buy Gilead rapidly advances long-acting injectible HIV drug based on SABER agreement. Yesterday, DURECT announced that it has earned a $10M milestone payment from Gilead (GILD; not rated) related to the further development of an investigational injectable HIV product utilizing DURECT’s SABER technology, as part of a license agreement that was announced in July 2019. In addition to the $25M upfront payment already received, remaining milestones include the potential for up to an additional $65M in development and regulatory milestones, up to an additional $70M in sales-based milestones, as well as tiered royalties on product sales." (9/10/2019)

Has DURECT been receiving favorable news coverage?

Press coverage about DRRX stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DURECT earned a daily sentiment score of -3.4 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutDURECT.

Who are some of DURECT's key competitors?

Some companies that are related to DURECT include Madrigal Pharmaceuticals (MDGL), Aurinia Pharmaceuticals (AUPH), Epizyme (EPZM), Zymeworks (ZYME), Corcept Therapeutics (CORT), Xencor (XNCR), Heron Therapeutics (HRTX), Ligand Pharmaceuticals (LGND), Zogenix (ZGNX), Dicerna Pharmaceuticals (DRNA), Theravance Biopharma (TBPH), Ironwood Pharmaceuticals (IRWD), Opko Health (OPK), BELLUS Health (BLUSF) and Y-mAbs Therapeutics (YMAB). View all competitors.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Novavax (NVAX), Cassava Sciences (SAVA), Catalyst Pharmaceuticals (CPRX), Gilead Sciences (GILD), Amarin (AMRN), Geron (GERN), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Verastem (VSTM) and Inovio Pharmaceuticals (INO).

Who are DURECT's key executives?

DURECT's management team includes the following people:

Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 62)
Mr. Matthew J. Hogan, CFO & Sec. (Age 59)
Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 62)
Mr. Michael H. Arenberg, Chief Financial Officer (Age 49)
Dr. John W. Gibson B.S., M.S., VP of Birmingham Operations & Principal Scientist

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.84%), Beirne Wealth Consulting Services LLC (0.98%), Geode Capital Management LLC (0.84%), Acadian Asset Management LLC (0.64%), Gagnon Securities LLC (0.57%) and Two Sigma Investments LP (0.51%). Company insiders that own DURECT stock include First Eagle Investment Managem, James E Brown, Jon S Saxe, Lp Bleichroeder and Michael Arenberg. View institutional ownership trends for DURECT.

Which major investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including Bleichroeder LP, Raymond James & Associates, Alpine Global Management LLC, Gagnon Securities LLC, Ironwood Investment Management LLC, Bank of New York Mellon Corp, State Street Corp, and Cowen Prime Services LLC. View insider buying and selling activity for DURECT.

Which major investors are buying DURECT stock?

DRRX stock was bought by a variety of institutional investors in the last quarter, including Parametric Portfolio Associates LLC, Two Sigma Advisers LP, Beirne Wealth Consulting Services LLC, Jane Street Group LLC, Two Sigma Investments LP, Morgan Stanley, Geode Capital Management LLC, and Acadian Asset Management LLC. Company insiders that have bought DURECT stock in the last two years include First Eagle Investment Managem, James E Brown, Jon S Saxe, Lp Bleichroeder, and Michael Arenberg. View insider buying and selling activity for DURECT.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $2.34.

How big of a company is DURECT?

DURECT has a market capitalization of $458.69 million and generates $29.56 million in revenue each year. The specialty pharmaceutical company earns $-20,580,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis. DURECT employs 88 workers across the globe.

What is DURECT's official website?

The official website for DURECT is www.durect.com.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.

This page was last updated on 5/31/2020 by MarketBeat.com Staff